33469-36-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Phenyl-4-(trifluoromethyl)-1H-imidazole is used as a potential pharmaceutical agent for its unique structure and biological activity. The trifluoromethyl group may impart specific properties that could be beneficial in the development of new drugs, such as enhanced lipophilicity or metabolic stability.
Used in Agrochemical Industry:
In the agrochemical field, 2-Phenyl-4-(trifluoromethyl)-1H-imidazole is used as a potential active ingredient in pesticides or herbicides. Its specific chemical structure may provide novel modes of action or selectivity against pests or weeds, contributing to more effective and targeted agricultural solutions.

InChI:InChI=1/C10H7F3N2/c11-10(12,13)8-6-14-9(15-8)7-4-2-1-3-5-7/h1-6H,(H,14,15)

Upstream product

• 670-96-2 2-Phenylimidazole 
• 2314-97-8 iodotrifluoromethane 
• 100-52-7 benzaldehyde 
• 111269-38-6 1,1,1-trifluoro-3-(dimethylhydrazono)-2-propanone 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 
• 2926-30-9 sodium triflate 
• 725-39-3 N-(3,3,3-trifluoro-2,2-dihydroxypropyl)benzamide 
• 495-69-2 Hippuric Acid 
• 106942-35-2 2-phenyl-4-(2,2,2-trifluoroacetyl)-4H-oxazol-5-one 

Downstream Products

• 77498-98-7 2-phenyl-3H-imidazole-4-carboxylic acid 
• 77498-98-7 2-phenyl-1H-imidazole-4-carboxylic acid 
• 1221277-42-4 (2-phenyl-1H-imidazol-4-yl)(piperidin-1-yl)methanone 
• 1221277-43-5 morpholino(2-phenyl-1H-imidazol-4-yl)methanone 
• 1221277-44-6 N-methyl-N,2-diphenyl-1H-imidazole-4-carboxamide 
• 1221277-45-7 N-(4-methoxyphenyl)-N-methyl-2-phenyl-1H-imidazole-4-carboxamide 
• 787563-21-7 2-phenyl-1-(pyridin-4-yl)-1H-imidazole-4-carboxylic acid 
• 787563-23-9 2-phenyl-1-(4-pyridyl)-1H-imidazole-4-carboxylic acid ethyl ester 
• 32683-00-4 ethyl 2-phenylimidazole-4-carboxylate 
• 1299491-22-7 N-(tert-butoxycarbonyl)-4-trifluoromethyl-2-phenylimidazole 

Relevant academic research and scientific papers

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

CYCLIC SULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ( TNF ) receptor associated protein 1 ( TRAP1 ) modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ( PINK1 ) loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

Inhibitors of matrix metalloproteinases

Compounds of general formula (I), salts or solvates thereof and pharmaceutical compositions containing same: wherein Z is N or CH or the Z(R1) part is replaced with a covalent bond, m and n is 0, 1, 2 or 3; HET is heteroaryl; X is CF3, halogen, CO-heterocyclyl, COOR3 or CONHR3; R1 is H, (CH2)o-aryl, (CH2)p-heteroaryl, (CH2)q-biphenyl; C(O)—R5; S(O)2—R6; R2 is H, aryl, heteroaryl, Y—(CH2)r-aryl, Y—(CH2)s-heteroaryl, where some of the above substituents may be substituted; Y is O or S; with the exclusion of the compound where HET is 1,3-thiazol, X is COOH, R1 is 4-fluorophenyl and R2 is benzyloxy. The invention also relates to the use of a compound of general formula (I), salts or solvates thereof for the use in the prevention or treatment of diseases where the activation of MMPs is involved in the pathomechanism. In this aspect the use of the above excluded compound is also inventive.

Direct trifluoromethylation of imidazoheterocycles in a recyclable medium at room temperature

Regioselective C-H trifluoromethylation of imidazoheterocycles with Langlois' reagent in a recyclable mixed medium of 1-butyl-3-methylimidazoliumtetrafluoroborate ([Bmim]BF4) and water at room temperature has been developed. In the presence of

Imidazole-derived agonists for the neurotensin 1 receptor

A scaffold-hop program seeking full agonists of the neurotensin-1 (NTR1) receptor identified the probe molecule ML301 (1) and associated analogs, including its naphthyl analog (14) which exhibited similar properties. Compound 1 showed full agonist behavior (79-93%) with an EC50 of 2.0-4.1 μM against NTR1. Compound 1 also showed good activity in a Ca mobilization FLIPR assay (93% efficacy at 298 nM), consistent with it functioning via the G q coupled pathway, and good selectivity relative to NTR2 and GPR35. In further profiling, 1 showed low potential for promiscuity and good overall pharmacological data. This report describes the discovery, synthesis, and SAR of 1 and associated analogs. Initial in vitro pharmacologic characterization is also presented.

4-trifluoroacetyl-2-phenyloxazol-5-one: Versatile template for syntheses of trifluoromethylsubstituted heterocycles

4-Trifluoroacetyl-2-phenyloxazol-5-one (1) is a versatile template for the synthesis of various trifluoromethyl-substituted heterocycles. Cyclocondesation of 1 with hydroxylamine and hydrazine afforded isoxazole and pyrazole, respectively. Another key protocol involves nucleophilic ring opening of 1 with H2O or MeOH to give a-amido trifluoromethyl ketones which are transformed into trifluoromethyl-substituted thiazoles, oxazoles, imidazoles, pyrazoles, and pyrimidines.

Synthesis of tertiary amides from anionically activated aromatic trifluoromethyl groups

Figure presented In this paper, a novel synthesis of tertiary amides from anionically activated aromatic trifluoromethyl groups is presented. Anionically activated trifluoromethyl groups react with secondary amines under aqueous conditions to afford tertiary amides. The mechanism involves initial elimination of hydrogen fluoride by an E1cB mechanism to afford an electrophilic quinone methide- or azafulvene-type intermediate that reacts with secondary amines under aqueous conditions to afford the tertiary amide in good yield (up to 99%).

Trifluoromethylation of various aromatic compounds by CF3I in the presence of Fe(II) compound, H2O2 and dimethylsulfoxide

Trifluoromethylation of aromatic and hetero-aromatic compounds by CF3I in the presence of Fe(II) compound, H2O2 and dimethylsulfoxide was investigated. Various trifluoromethylated benzene derivatives, six-membered nitrogen-containing aromatic compounds and five-membered hetero-aromatic compounds were obtained under mild conditions. General orientation of electrophilic substitution of aromatic compounds was observed similarly as reported in other radical trifluoromethylation previously.

Certain pyrazoline derivatives with kinase inhibitory activity

The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.